A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 145 participants.
Also called NCT03267108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 145 participants
- Registry
-
NCT03267108
-
- Other papers using this trial's data
- Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Terminated
Technical summary
Registry record NCT03267108. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-14 (actual); primary completion 2023-06-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
- Acronym
- REBUILD
- Condition
- Pulmonary Fibrosis
- Condition
- Pulmonary Hypertension
- Intervention (Combination product)
- INOpulse®
- Intervention (Combination product)
- Placebo
- Intervention (Combination product)
- Open Label Extension
- Lead sponsor
- Bellerophon Pulse Technologies
Record details
- Record id
cardio:ct-nct03267108- Content hash
1be7dc26791748a336b3674a2310acd97dd1e794bf666648a4080c577304a8d2